Patrick Larson

2.6k total citations
51 papers, 1.9k citations indexed

About

Patrick Larson is a scholar working on Pharmacology, Oncology and Infectious Diseases. According to data from OpenAlex, Patrick Larson has authored 51 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 11 papers in Oncology and 8 papers in Infectious Diseases. Recurrent topics in Patrick Larson's work include Inflammatory mediators and NSAID effects (11 papers), HIV/AIDS drug development and treatment (8 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Patrick Larson is often cited by papers focused on Inflammatory mediators and NSAID effects (11 papers), HIV/AIDS drug development and treatment (8 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Patrick Larson collaborates with scholars based in United States, United Kingdom and Canada. Patrick Larson's co-authors include Keith Gottesdiener, John A. Wagner, Barry J. Gertz, Kenneth C. Lasseter, Tom Doebber, David E. Moller, David B. Savage, Anders H. Berg, Joel P. Berger and Stephen O’Rahilly and has published in prestigious journals such as Annals of Internal Medicine, American Journal of Clinical Nutrition and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Patrick Larson

48 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick Larson United States 21 601 466 449 398 308 51 1.9k
Frederico Teixeira Portugal 29 527 0.9× 306 0.7× 263 0.6× 565 1.4× 598 1.9× 92 3.1k
Inge De Lepeleire United States 28 480 0.8× 147 0.3× 563 1.3× 278 0.7× 186 0.6× 80 2.4k
Jun Goo Kang South Korea 23 333 0.6× 284 0.6× 384 0.9× 514 1.3× 690 2.2× 102 2.0k
K. Williams Australia 12 271 0.5× 358 0.8× 301 0.7× 171 0.4× 129 0.4× 18 1.2k
Komal Sodhi United States 31 607 1.0× 447 1.0× 136 0.3× 1.0k 2.6× 463 1.5× 83 2.5k
Jean‐Pierre Desager Belgium 22 388 0.6× 384 0.8× 156 0.3× 479 1.2× 334 1.1× 48 2.3k
Wesley Tanaka United States 19 422 0.7× 131 0.3× 505 1.1× 946 2.4× 867 2.8× 33 2.8k
Józef Drzewoski Poland 34 638 1.1× 380 0.8× 226 0.5× 1.5k 3.8× 779 2.5× 137 3.8k
Bradley L. Urquhart Canada 26 416 0.7× 479 1.0× 139 0.3× 933 2.3× 193 0.6× 79 2.9k
Mark S. Paller United States 33 648 1.1× 152 0.3× 180 0.4× 1.0k 2.5× 189 0.6× 70 4.2k

Countries citing papers authored by Patrick Larson

Since Specialization
Citations

This map shows the geographic impact of Patrick Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Larson more than expected).

Fields of papers citing papers by Patrick Larson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Larson. The network helps show where Patrick Larson may publish in the future.

Co-authorship network of co-authors of Patrick Larson

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Larson. A scholar is included among the top collaborators of Patrick Larson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Larson. Patrick Larson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Larson, Patrick, et al.. (2018). Make room for iodine: systematic pore tuning of multivariate metal–organic frameworks for the catalytic oxidation of hydroquinones using hypervalent iodine. Catalysis Science & Technology. 8(17). 4349–4357. 26 indexed citations
2.
Larson, Patrick, et al.. (2018). Synthesis, characterization, electrochemical properties and theoretical calculations of (BIAN) iron complexes. Polyhedron. 159. 365–374. 10 indexed citations
3.
Larson, Patrick, et al.. (2018). Anchored Aluminum Catalyzed Meerwein–Ponndorf–Verley Reduction at the Metal Nodes of Robust MOFs. Inorganic Chemistry. 57(12). 6825–6832. 18 indexed citations
4.
Krishna, Rajesh, Wen‐Lin Luo, Patrick Larson, & Paul Fackler. (2017). On the Use of Group Sequential Study Designs for the Test of Bioequivalence for Complicated Products. Journal of Pharmaceutical Sciences. 106(10). 3167–3170.
5.
Krishna, Rajesh, Matthew L. Rizk, Patrick Larson, et al.. (2016). Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir. Therapeutic Innovation & Regulatory Science. 50(6). 777–790. 2 indexed citations
6.
Krishna, Rajesh, et al.. (2016). Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. Journal of Pharmacy and Pharmacology. 68(11). 1359–1365. 18 indexed citations
7.
Herman, Gary, Goutam C. Mistry, Bingming Yi, et al.. (2010). Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males. British Journal of Clinical Pharmacology. 71(3). 429–436. 29 indexed citations
8.
Stoch, S. Aubrey, Evan Friedman, A. Maes, et al.. (2009). Effect of Different Durations of Ketoconazole Dosing on the Single‐Dose Pharmacokinetics of Midazolam: Shortening the Paradigm. The Journal of Clinical Pharmacology. 49(4). 398–406. 38 indexed citations
9.
Lauring, Brett, Victor Dishy, Wen‐Lin Luo, et al.. (2009). Laropiprant in Combination With Extended‐Release Niacin Does Not Alter Urine 11‐Dehydrothromboxane B2, a Marker of In Vivo Platelet Function, in Healthy, Hypercholesterolemic, and Diabetic Subjects. The Journal of Clinical Pharmacology. 49(12). 1426–1435. 12 indexed citations
10.
Schwartz, Jules I., Aimée Dallob, Patrick Larson, et al.. (2008). Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects. The Journal of Clinical Pharmacology. 48(6). 745–754. 35 indexed citations
11.
Krishna, Rajesh, Arthur Bergman, Patrick Larson, et al.. (2007). Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects. The Journal of Clinical Pharmacology. 47(2). 165–174. 56 indexed citations
12.
Bergman, Arthur, Joanne Burke, Patrick Larson, et al.. (2006). Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects. The Journal of Clinical Pharmacology. 46(3). 321–327. 23 indexed citations
13.
Ward, Leanne M., Andrew Denker, Arturo G. Porras, et al.. (2005). Single-Dose Pharmacokinetics and Tolerability of Alendronate 35- and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I. The Journal of Clinical Endocrinology & Metabolism. 90(7). 4051–4056. 47 indexed citations
14.
Schwartz, Jules I., Patrick Larson, Arturo G. Porras, et al.. (2003). Pharmacokinetic Evaluation of Rofecoxib. Clinical Drug Investigation. 23(8). 503–509. 2 indexed citations
15.
Agrawal, Nancy, Mark J. Rose, Catherine Z. Matthews, et al.. (2003). Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment. The Journal of Clinical Pharmacology. 43(10). 1136–1148. 19 indexed citations
16.
Bachmann, Kenneth, Donald B. White, Luis Jáuregui, et al.. (2003). An Evaluation of the Dose‐Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe. The Journal of Clinical Pharmacology. 43(10). 1082–1090. 21 indexed citations
17.
Rodrigues, A. David, Rita A. Halpin, Leslie A. Geer, et al.. (2003). Absorption, Metabolism, and Excretion of Etoricoxib, a Potent and Selective Cyclooxygenase-2 Inhibitor, in Healthy Male Volunteers. Drug Metabolism and Disposition. 31(2). 224–232. 64 indexed citations
18.
Larsen, Thomas Meinert, Søren Toubro, Marleen A. van Baak, et al.. (2002). Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men. American Journal of Clinical Nutrition. 76(4). 780–788. 137 indexed citations
19.
Smet, M. De, et al.. (1998). Influence of the selective cyclooxygenase-2 inhibitor, MK-0966 [MK], on digoxin [DG] serum concentrations. Naunyn-Schmiedeberg s Archives of Pharmacology. 358(1). 1 indexed citations
20.
Zhao, Jamie J., John Rogers, Sherry D. Holland, et al.. (1997). Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharmaceutics & Drug Disposition. 18(9). 769–777. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frederico Teixeira Breakdown of academic impact, for papers by Inge De Lepeleire Breakdown of academic impact, for papers by Jun Goo Kang Breakdown of academic impact, for papers by K. Williams Breakdown of academic impact, for papers by Komal Sodhi Breakdown of academic impact, for papers by Jean‐Pierre Desager Breakdown of academic impact, for papers by Wesley Tanaka Breakdown of academic impact, for papers by Józef Drzewoski Breakdown of academic impact, for papers by Bradley L. Urquhart Breakdown of academic impact, for papers by Mark S. Paller
Rankless by CCL
2026